Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7621597 | 0.98 | CHUK (0.50) | CHUKLMNAHTTPKMHSD17B10 | |
| SCHEMBL7626873 | 0.95 | CHUK (0.47) | CHUKLMNAHTTPKMHSD17B10 | |
| SCHEMBL133156 | 0.92 | CHUK (0.45) | CHUKLMNAHTTPKMHSD17B10 | |
| SCHEMBL30590050 | 0.92 | CHUK (0.45) | CHUKLMNAHTTPKMHSD17B10 | |
| Hydrochloric Acid SCHEMBL8971259 | 0.91 | CHUK (0.44) | CHUKLMNAHTTPKMHSD17B10 | |
| SCHEMBL5442344 | 0.82 | KMT2A (0.51) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL16146752 | 0.82 | LMNA (0.47) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL16146719 | 0.82 | LMNA (0.47) | CHUKLMNAHTTPKMHSD17B10 | |
| SCHEMBL1803029 | 0.82 | LMNA (0.47) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL5439050 | 0.82 | KMT2A (0.51) | LMNAHTTPKMHSD17B10PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-10711002-B2 | Purine compounds and method for the treatment of cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2020-07-14 | — | — | US | disclosed |
| US-10711002-B2 | Purine compounds and method for the treatment of cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2020-07-14 | — | — | US | disclosed |
| US-20190119279-A1 | PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2019-04-25 | — | — | US | disclosed |
| US-20190119279-A1 | PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2019-04-25 | — | — | US | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| WO-2017181285-A1 | PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017181285-A1 | PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-10-26 | — | — | WO | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| US-20130231307-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2616474-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | Centre National De La Recherche Scientifique (FR) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012034719-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | CHUK 426/4885LMNA 599/4885HTT 3291/4885 |
| US-10711002-B2 | Purine compounds and method for the treatment of cancer | PNP, NUDT1, HPRT1 | CHUK 516/4885LMNA 3041/4885HTT 4707/4885 |
| US-20130231307-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | PNP, TYMP, EIF2AK2 | CHUK 1599/4885LMNA 3155/4885HTT 3727/4885 |
| US-20190119279-A1 | PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | PNP, NUDT1, HPRT1 | CHUK 516/4885LMNA 3041/4885HTT 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.